Peter Culpepper Tumblr Blog
At Provectus Biopharmaceuticals, Peter Culpepper heads the SEC filing division and manages investor financing for the company in order to facilitate the firm's work as a biopharmaceutical company specializing in dermatology and oncology therapies. Mr. Culpepper works in concert with lawyers and auditors to ensure that Provectus complies entirely with SOX 404. He also oversees the company's management structure and presents his recommendations about management to the Board of Directors.
Prior to joining Provectus Biopharmaceuticals in 2004, Peter Culpepper served for three years as a Management Consultant at Felix Culpepper International, Inc. He worked with corporations in all stages of development on a wide range of questions including valuation, business planning, and fundraising. Peter Culpepper is formerly a registered representative with AXA Advisors, LLC.
From 2000 to 2001, Peter Culpepper was Corporate Controller and Chief Accounting Officer of Neptec, Inc., a fiber-optic component manufacturer. In this role, he also served as Corporate Secretary of Management on the board of the company, participating in a wide range of auditing activities and pre-IPO preparations.
Peter Culpepper held a number of positions at Metromedia Affiliated Companies between 1998 and 2000, including serving as Group Finance Director of Metromedia International Group in Austria, Assistant Corporate Controller of Metromedia International Group in the United States, and Network Controller of Metromedia Fiber Network. From 1993 to 1998, Peter Culpepper worked as Accounting Manager, Assistant Regional Controller, National Accounts Division Controller, and finally Director of Accounting at Paging Network, Inc.
Peter Culpepper holds a BA in Philosophy from The College of William & Mary, an Associate of Applied Science (AAS) in Accounting from Northern Virginia Community College (NOVA), and an MBA in Finance from the University of Maryland's Robert H. Smith School of Business.
Based in Knoxville, Tennessee, Peter Culpepper serves as the chief operating officer and chief financial officer of Provectus Biopharmaceuticals, Inc. At the beginning of 2016, Peter Culpepper also became the interim chief executive officer for Provectus, a clinical-stage biopharmaceutical company that develops dermatology therapies and oncology treatments for various cancers.
In February of 2016, Provectus highlighted data on the immunologic outcomes of its investigational cancer therapy, PV-10, on colon cancer cells at the 11th Annual Academic Surgical Congress. The abstract was presented by a member of the research team, N. M. Kunda, who works in oncology at the University of Illinois at Chicago.
During the presentation in Jacksonville, Florida, Dr. Kunda reported that PV-10 showed signs of being toxic to cells during in vitro tests on colon cancer. Dr. Kunda also noted that testing showed evidence of cell arrest, autophagy, apoptosis, and endoplasmic reticulum stress. Provectus’ chief technology officer, Eric Wachter, stated that the data presented at the conference further explains the mechanisms behind PV-10’s effect on solid tumors as an ablative immunotherapy.
